



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE PATENT & TRADEMARK OFFICE

SHEET 1 OF 2
(REV. 7-80)**LIST OF REFERENCES CITED BY APPLICANT**

(Use Several Sheets if Necessary)

DOCKET NO.:

2420/11249US2

SERIAL NO:

10/076,905

APPLICANT:

Ze'ev RONAI

FILING DATE:

February 14, 2002

CONFIRMATION NO: 1884

U.S. PATENT DOCUMENTS

<u>*EXAMINER</u> <u>INITIALS</u>	<u>DOCUMENT</u> <u>NUMBER</u>	<u>DATE</u>	<u>NAME</u>	<u>CLASS</u>	<u>SUBCLASS</u>	<u>FILING DATE</u>
-------------------------------------	----------------------------------	-------------	-------------	--------------	-----------------	--------------------

FOREIGN PATENT DOCUMENTS

<u>*EXAMINER</u> <u>INITIALS</u>	<u>DOCUMENT</u> <u>NUMBER</u>	<u>DATE</u>	<u>COUNTRY</u>	<u>CLASS</u>	<u>SUBCLASS</u>	<u>TRANSLATION</u> <u>YES</u> <u>NO</u>
-------------------------------------	----------------------------------	-------------	----------------	--------------	-----------------	--

OTHER REFERENCES**(INCLUDING AUTHOR, TITLE DATE, PERTINENT PAGES, ETC.)***EXAMINER
INITIALS

- SR 1. Bhounik *et al.*, Clin. Cancer Res. 2001; 7(2):331-42. ✓
- SR 2. Ivanov, V.N., and Ronai, Z., Oncogene 2000; 19: 3003-3012. ✓
- SR 3. Ivanov, V.N. *et al.*, Oncogene 2000; 19: 933-942. ✓
- SR 4. Yang, Y.-M *et al.*, Oncogene, 12 :2223-2233, 1996. ✓
- SR 5. Ronai, Z. *et al.*, Oncogene 1998; 16: 523-531. ✓
- SR 6. Ivanov, V.N. *et al.*, J. Biol. Chem. 1999; 274:14079-14089. ✓

1 ~~~~~

12/15/04

LIST OF REFERENCES CITED BY APPLICANT

(Use Several Sheets if Necessary)

DOCKET NO.: 2420/11249US2
APPLICANT: Ze'ev RONAISERIAL NO: 10/076,905
FILING DATE: February 14, 2002
CONFIRMATION NO: 1884***EXAMINER
INITIALS**


- 82 7. Gupta, S. *et al.*, Science 1995; 267: 389-393. ✓
- 82 8. Fuchs, S.Y. and Ronai, Z., Mol. Cell Biol. 1999; 19: 3289-3298. ✓
- 52 9. Georgopoulos, K. *et al.*, Mol. Cell. Biol. 1992; 12: 747-757. ✓
- 52 10. Huguier S. *et al.*, Mol. Cell Biol. 1988; 18:7020-7029. ✓
- 52 11. Bhounik, A. *et al.*, ATF-2 derived peptide sensitizes melanoma to treatment and inhibits in vivo growth and metastasis through altered ATF-2 and c-Jun transcriptional activities. (manuscript submitted to *Cancer Cell*) ✓

EXAMINER: _____

DATE CONSIDERED: _____

***EXAMINER:**

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



PTO/SB/08a/b (08-03)
Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Patent Mark Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/076,905
				Filing Date	February 14, 2002
				First Named Inventor	Ze'ev Ronai
				Art Unit	1642
				Examiner Name	Steven L. Rawlings, Ph.D.
Sheet	1	of	1	Attorney Docket Number	02420/100I249-US2

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			


FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ⁴ -Number ⁴ -Kind Code ⁵ (if known)				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
SR	CA	Anindita Bhounik et al., "An ATF2-Derived Peptide Sensitizes Melanomas to Apoptosis and Inhibits Their Growth and Metastasis," September 2002, vol. 110, no. 5, pp. 643-650.		
SR	CB	Anindita Bhounik et al., "Transcriptional Switch By Activating Transcription Factor 2-Derived Peptide Sensitizes Melanoma Cells to Apoptosis and Inhibits Their Tumorigenicity," March 23, 2004, vol. 101, no. 12, pp. 4222-4227.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	12/15/04
-----------------------	---	--------------------	----------